anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It is an observational study, monocentric, prospective. This study consists in collecting data from an anonymized questioner given to patients presenting themselves at the emergency department of Clermont-Ferrand University Hospital. Answers to the questions will not change the patient's management. The questioner, containing 17 questions, requires answering "yes" or "no" by ticking boxes, or even specify when it is stipulated. This questionnaire will be given to the patient after his registration, and filled by the latter in the waiting room, pending medical care. Answering the questionnaire will take between 5 to 10 minutes. The data is anonymous.

The patient arrives at the emergency department and registers at the entrance desks where a paper and computer file is created. Then, the Reception and Orientation Nurse takes care of the patient by welcoming him in the reception box, she realizes the taking of the hemodynamics constants, the collection of the reason of consultation with the grievances of the patient. During this phase, patient will be inform of the completion of this study and asked to participate in this study. If the patient agrees to participate, an anonymized questioner will be provided and explained by one of the investigating physicians or associated partners.
Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
Air dried Cannabis flowers are ground to fine power and heated to 120 C to decarboxylate cannabinoids to active ingredients. Ethanol was effective for extraction, with drying under vacuum prior to washing away polar contaminants in water to increase purity. Extraction in 100% ethanol leached almost all active ingredient but also extracted some water-soluble contaminants. 80% ethanol extracted half the active ingredient contaminated by twice as much total mass of other materials. Extracted cannabinoids may be further collected over quaternary amine chromatography resin and eluted with organic solvents. The invention may heat-activate, extract and partition cannabinoids with a high efficiency using an oven, water, potable ethanol, a filter with a cold trap and vacuum pump to safely recover solvents.
Bile acids are absorbed from the small intestine by an passive and an active mechanism. The active mechanism involves a Na+/bile acid cotransporter. A cDNA encoding the ileal bile acid cotransporter has been isolated and sequenced. The amino acid sequence of the cotransporter protein is also disclosed. The renal bile acid cotransporter is also shown to be identical to the ileal cotransporter. The cotransporter disclosed herein will have use in treatment of hypercholesterolemia, diabetes, heart disease and liver disease. In addition, methods of screening man made and naturally occurring substances for the discovery of new bile acid transport inhibitors and activators and methods of detecting mutations in human ileal/renal bile acid transporter genes are disclosed.
The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31°C, and of poor replication or incapable of replication at about 37°C or higher.
1,217,208. Oxadithia-adamantanoles and process for their manufacture. PHARMACIA AB. 27 Feb., 1968 [28 Feb., 1967], No. 9367/69. Heading C2C. The invention comprises oxadithia-adamantanoles having the general formula wherein R 1 -R 9  are each hydrogen or an alkyl group having 1 to 6 carbon atoms and X, Y and Z are each oxygen or sulphur, one of the symbols being oxygen and the remaining two being sulphur atoms. These compounds may be prepared by reacting diones of formulµ wherein R 1 -R 9  have each the above significance, with hydrogen sulphide in strongly acid solution. The radicals R 1 -R 9  may be so chosen that the two diones are the same so that a single dione is used as starting material. Pharmaceutical compositions comprising the compounds of the invention as the active ingredients are found effective for the treatment of psychial derangements.
Patients undergoing hemodialysis experience pain, anxiety and stress due to large-gauge needle punctures necessary to ensure efficient arteriovenous fistula flow. In addition, anxiety disorders are prevalent in hemodialysis patients, primarily caused by invasive procedures and dialysis machine alarm sounds. Patients describe worry about the success of needling and resigned acceptance of pain and anxiety about dialysis needles. Therefore, when performing an AVF puncture, nursing care should prioritise the management of pain and anxiety. With this background in mind, mirror therapy has been introduced as one of the non-pharmacological interventions in the domain of pain management. It has been reported that viewing the picture of a healthy limb could moderate pain perception in the affected one
BACKGROUND AND OBJECTIVES: The impact of dominant stricture (DS) on the outcomes of paediatric-onset primary sclerosing cholangitis (PSC) is unknown. This study was aimed at investigating the impact of DS on the clinical course and prognosis of patients with paediatric-onset PSC.
METHODS: Patients with paediatric-onset PSC diagnosed between January 1993 and May 2017 were identified from hospital records or our PSC registry. Data including clinical, laboratory, cholangiography, and cytology at diagnosis and during follow-up (until July 2023) were reviewed. We graphed the Kaplan-Meier failure function and fitted crude and multivariable Cox model to calculate hazard ratios (HR) and 95% confidence intervals (CI) for selected variables. In these analyses, DS was treated as a time-varying variable.
RESULTS: We identified 68 patients (42 males) with paediatric-onset PSC (median age at diagnosis 15 years). The median follow-up was 13 years and the median age at the last follow-up was 27 years. In total, 35 (51%) had concomitant autoimmune hepatitis. DS was diagnosed in 33 patients (48%): in eight at the time of PSC diagnosis (12%) and in 25 (37%) by the end of follow-up. In patients with DS, two developed cirrhosis, seven were transplanted and one patient was operated for a biliary mass with low-grade dysplasia. In patients without a DS, two developed cirrhosis, and four were transplanted; one female was excluded from survival analysis because she already had cirrhosis at the time of PSC diagnosis. Cirrhosis or biliary dysplasia or needing liver transplantation for these indications were more frequent after the development of DS (10/33, adjusted HR 4.26, 95%CI: 1.26-14.4). No cholangiocarcinomas or deaths occurred during the follow-up.
CONCLUSIONS: DS was present at diagnosis or developed during follow-up in about half of the patients with paediatric-onset PSC and was associated with impaired outcome.
After selective caries removal the cavity was irradiated in contact mode with continuous wave of radiation through a 400µm flexible fiber that was inserted inside the cavity with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. Irradiation time was 15 seconds and repeated three times for 15 seconds interval with contact, pulsed mode and the output power was adjusted at 1.30 Watt.
PURPOSE:To obtain erythropoietin stably in a large amount at a low cost, by cultivating an established cell, having the ability to produce the erythropoietin, and derived from the human liver in a suitable culture medium to produce the titled substance in the culture. CONSTITUTION:An established cell, e.g. huH-2 strain, having the ability to produce erythropoietin (EPO), and derived from the human liver is cultivated in a suitable culture medium e.g. a synthetic culture medium containing 1-25% blood serum, preferably under conditions of low partial pressure of oxygen to produce EPO in the culture. The resultant culture fluid is collected and treated, e.g. salted out, dialyzed, filtered, centrifuged, concentrated, freeze-dried, etc. to give easily EPO (a substance which is a kind of hematogenic hormones, produced and secreted by the kidney, and acting on erythroblastic precursor cells to differentiate them into erythrocytes such as glycoprotein having 30,000-40,000 molecular weight). USE:A remedy for anemia caused by renal insufficiency, diagnostic agent or research reagent, etc.
The present invention relates to a method of desensitizing a human host to allergic dermatitis resulting from ecto-parasitic bites, in particular fleas. The invention describes a method to identify a human susceptible to or having allergic dermatitis effected by said ecto-parasitic bites. Bites from ecto-parasites, in particular fleas, can cause a hypersensitive response in animals. In particular, hypersensitive response to fleabites is manifested in a disease called flea allergy dermatitis (FAD). Hypersensitive responses include Type I, II, III and IV hypersensitivities. The invention relates to identifying a human susceptible to or having allergic dermatitis by measuring the presence of antibodies indicative of allergic dermatitis, by contacting a formulation with a body fluid from said human under conditions sufficient for formation of an immunocomplex between said formulation and said antibodies. If present, the composition comprising at least one isolated ecto-parasite saliva protein, wherein said ecto-parasite saliva protein comprises at least a portion of an amino acid sequence, wherein said portion is encoded by a nucleic acid molecule that hybridises under stringent conditions with a nucleic acid molecule that encodes a flea saliva protein selected from the group consisting of fspA, fspB, fspC1, fspC2, fspD1, fspD2, fspE, fspF, fspG1, fspG2, fspG3, fspH, fspI, fspJ, fspK, fspL1, fspL2, fspM1, fspM2, fspN1, fspN2 and fspN3 flea saliva extracts.
PURPOSE:To economically obtain an electronic clinical chart system which has a function equal to a case whose a large capacity recording medium to each patient. CONSTITUTION:A 1st recording medium 1 of large capacity and a 2nd recording medium of small capacity which has the same external shape and the same handling way as the medium 1 are properly used for each patient. The medium 2 corresponds to a part 20 of a storage area of the medium 1 and records the clinical chart information in the first medical examination. If the information exceeds the capacity of the medium 2, the information so far stored in the medium 2 are transferred to the medium 1. Thereafter the information are all stored in the medium 1. That is, the medium 1 is substantially assigned to each patient in terms of the logical sense and the handling performance. Thus the electronic clinical chart system which is free from any economical problem caused by the price of a large capacity recording medium is realized.
BACKGROUND: Immune checkpoint inhibitors (ICIs) represent a paradigm shift in the development of cancer therapy. However, the improved efficacy of ICIs remains to be further investigated. We conducted a systematic review and meta-analysis to evaluate the pan-immunoinflammatory value (PIV) and PILE score used to predict response to ICI therapy.
METHODS: We searched selected databases for studies on pan-immune inflammation values and their association with outcomes of treatment with immune checkpoint inhibitors. We used hazard ratios (HRS) and 95% confidence intervals (CI) to summarize survival outcomes. All data analyses were performed using STATA 15.0.
RESULTS: 7 studies comprising 982 patients were included in the meta-analysis. The pooled results showed that higher PIV was significantly associated with shorter overall survival OS (HR = 1.895, 95%CI: 1.548-2.318) and progression-free survival (PFS) (HR = 1.582, 95%CI: 1.324-1.890). Subgroup analyses also confirmed the reliability of the results.
CONCLUSIONS: High PIV and PILE metrics are associated with lower survival in cancer patients receiving ICIs.
PROBLEM TO BE SOLVED: To obtain a natural killer(NK) cell activation agent that is safe and shows the NK cell activation action, when it is orally given to human without toxicity to human and is useful as a material for physiologically functional foods. SOLUTION: This NK cell activation agent includes an oligoglucosamin as an active ingredient. The activation agent is preferably prepared as an oral administration product. In a preferred embodiment, this oligoglucosamine is obtained by hydrolyzing chitosan with chitosanase. In addition, it is preferable that the oligoglucosamin usually includes the trimer to hexamer of glucosamin in an amount of >=50 wt.%, particularly >=70 wt.% based on the whole glucosamins. The content of the oligoglucosamin is usually >=0.1 wt.%, when it is added to foods and is usually >=10 wt.%, when it is used as an oral oligoglucosamin preparation, or the like.
In patients with impaired kidney function, dietary phosphorus can not be completely excreted, which leads to elevated levels of serum phosphorus. Elevated serum phosphorus leads to increased levels of parathyroid hormone (PTH), and is associated with bone disease and other adverse consequences such as soft-tissue and vascular calcification, and increased morbidity and mortality. It is therefore important to prevent hyperphosphatemia and maintain serum phosphorus levels within the range recommended by K/DOQI. In patients on dialysis, phosphate binders are routinely used to control serum phosphorus by absorbing dietary phosphate during the transit through the intestine. However, the use of phosphate binders for non-dialyzed patients with chronic kidney disease (CKD) is not an FDA approved indication, although some physicians treat patients prior to dialysis based on clinical judgment. The goal of this study is to demonstrate the efficacy of calcium acetate (PhosLo) in controlling serum phosphorus in patients with moderate to severe decrease in kidney function.
BACKGROUND: Patients with chronic liver disease (CLD) frequently suffer from malnutrition and bone diseases, both of which heighten the risk of poor clinical outcomes. This study investigated the relationship between geriatric nutritional risk index (GNRI) and osteoporosis or fracture risk using the fracture risk assessment tool (FRAX) in patients with CLD.
METHODS: This cross-sectional study included 209 consecutive patients with CLD. The participants were divided into two groups: the all-risk group (GNRI ≤ 98.0) with nutrition-related risk and the no-risk group (GNRI > 98.0) without nutrition-related risk. Osteoporosis was diagnosed according to the World Health Organization criteria. The FRAX was used to estimate the 10-year probabilities of hip fracture (FRAX-HF) and major osteoporotic fracture (FRAX-MOF).
RESULTS: Of the 209 patients, 72 (34.4%) had osteoporosis. The all-risk group had a significantly higher prevalence of osteoporosis than the no-risk group (p < 0.001). Conversely, patients with osteoporosis had significantly lower GNRI than those without osteoporosis (p < 0.001). Multivariate analysis found lower GNRI to be a significant and independent risk factor for osteoporosis (odds ratio [OR], 0.927; p < 0.001) and high fracture risk derived from FRAX (without BMD) (OR, 0.904; p = 0.009). GNRI had a positive correlation with bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip, but a negative correlation with FRAX-HF and FRAX-MOF in the FRAX with and without BMD (p < 0.001 for all). The cutoff value of GNRI for predicting osteoporosis was 104.9, with sensitivity of 0.667 and specificity of 0.657.
CONCLUSIONS: The GNRI was significantly associated with osteoporosis and FRAX-derived fracture risk in patients with CLD, suggesting that it could be a simple and useful indicator for the management of bone diseases.
Approximately 6.2 million Americans have heart failure (HF) and the prevalence is increasing rapidly. HF is a common cause of hospitalization and mortality in older adults, and the cost of hospital care for HF is skyrocketing. One reason why HF is so burdensome and costly is that it is often complicated by cardiovascular and noncardiovascular comorbidities, especially in older patients. Psychiatric and medical disorders that are risk factors for incident HF persist after HF has developed, and additional comorbidities accumulate as patients with HF grow older. Thus, HF is embedded within a larger pattern of multimorbidity. Unfortunately, most trials of HF therapies as well as many other studies of HF have excluded patients with complex psychiatric and medical comorbidities or severe cognitive impairment. This has left large gaps in research on the care of older adults with HF. In addition, research on socioeconomic risk factors and health disparities has not been integrated with research on multimorbidity in HF. Heart failure is only one of multiple challenges facing patients with multimorbidity, stressful socioeconomic circumstances, and psychosocial problems, but the fragmentation of research on HF has left us with little understanding of patients with complex psychosocial problems. The purpose of this study is to identify combinations of comorbidities and health disparities may affect HF outcomes and require different mixtures of medical, psychological, and social services to address. It will encompass both psychiatric and medical comorbidities but will emphasize the role of psychiatric comorbidities. Syndemics theory is a useful framework for studying this type of psychosocial and medical complexity. Syndemics, also known as synergistic epidemics, occur when there are adverse interactions between prevalent disorders that concentrate in populations that are vulnerable due to adverse socioeconomic or environmental conditions. The syndemics framework has yielded important insights into a number of other disorders, but it has not been used to study the complex psychosocial problems of patients with HF. To our knowledge, this will be the first study of the syndemics of psychiatric and medical comorbidities in heart failure. The multimorbidity framework is an alternative approach for investigating the effects of multiple comorbidities on health outcomes. The specific aims of the study are: 1) to determine the coprevalence of major psychiatric and medical comorbidities in patients with HF (n=535); 2) to determine whether coprevalent comorbidities have synergistic effects on all-cause readmission and mortality risks, heart failure self-care, and perceived global health; 3) to identify vulnerable subpopulations of patients with HF who have higher coprevalences of syndemic comorbidities compared to less vulnerable subpopulations; 4) to determine the extent to which syndemic comorbidities explain adverse HF outcomes (readmissions and mortality, poor self-care, and poor perceived health) in vulnerable subgroups of patients with HF; and 5) to determine the effects of multimorbidity on readmissions, mortality risk, self-care, and quality of life.
Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including Lexapro. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH), and was reversible when Lexapro was discontinued. Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Geriatric Use (8.5)]. Discontinuation of Lexapro should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. 

Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.
<P>PROBLEM TO BE SOLVED: To provide a technique for reducing the burden of patients and an institution to which inspections are requested and for developing cooperation in community medical services.  <P>SOLUTION: The diagnostic institution for diagnosing the patients, the inspection institution for taking photos of the patient images and creating patient images, and a filming center for outputting the patient images to a film are connected by a network. A diagnostic institution terminal which transmits patient information to the inspection institution is installed in the diagnostic institution. An image diagnostic device which takes photos of the patients and creates the patient images based on the received patient information, and an inspection institution terminal which is installed in the inspection institution and transmits the patient images to the filming center are installed in the inspection institution. An imager which outputs the received patient image to a film is installed in the filming center.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Radiation quantity used in medicine is expanding year on year with increasing clinical uses for medical illnesses and to visualize instruments being used during procedures such as cardiac devices including pacemakers. The effects of radiation are not only on the patients for their procedure but also a cumulative effect of radiation on the operators. The stochastic effects of radiation have been well reported in the literature. Advancing technologies such as 3-dimensional(3D) mapping systems have allowed for leads to be identified using a 3D matrix and safely deployed to the myocardium. However, there are significant costs associated with the use of 3D mapping systems resulting in this approach not being widely adopted. Ultrasound use during implantation of cardiac implantable electronic devices (CIED) has been utilized in the past to gain vascular access via the axillary vein with good safety results. Experimental studies to visualize leads in the heart and venous systems using 3D ultrasound showed optimism but has not translated to clinical use due to lack of technology to improve the spatial and temporal resolution. The technology in imaging resolution has improved over the last 5 years and likely can be used to visualize a pacing lead in the heart. Techniques such as intravascular cardiac ultrasound have been used to assist in implanting lead via coronary sinus in individuals who can have contrast allergies. Therefore, transthoracic echocardiogram and ultrasound should be now of sufficient quality to allow for successful pacemaker insertion.

To date, there has not been a feasibility study to evaluate complete ultrasound and echocardiography-assisted pacemaker insertion.

In this study, the investigators aim to utilize ultrasound and echocardiography to gain vascular access and to direct the pacing lead into the right ventricle to allow for safe pacemaker implantation. If this is successful, then this will allow for a larger study to be conducted for single chamber devices including implantable cardioverter defibrillators. Moreover, the investigators will be able to analyze the cost-effectiveness of this new technique compared to the conventional technique of pacemaker implantation.